Health professionals are invited to provide input on puberty blockers for independent review
Primary healthcare professionals and community members are invited to provide their input on the independent review of the prescribing of puberty blockers and gender-affirming therapies in Queensland’s public paediatric gender services by Tuesday 29 July 2025.
The review is examining the evidence and ethical considerations surrounding the use of puberty suppression (Stage 1) and gender affirming (Stage 2) hormone therapies to treat children with gender dysphoria in the public health system.
About the independent review on puberty blockers and gender-affirming therapies
Earlier this year, the Queensland Government put an immediate pause on new trans patients under the age of 18 accessing puberty blockers (Stage 1) and gender-affirming (Stage 2) hormone therapies in the public health system.
This pause on the use of Stage 1 and Stage 2 hormone therapies on children in Queensland Health facilities will remain in place until after the report has been completed and its findings considered.
Queensland Health Director-General Dr David Rosengren said the review aims to help clinicians deliver the safest and most effective care for children with gender dysphoria.
It’s important that the review receives input from experts in relevant specialties and the people affected, including former and current patients of paediatric gender health services.
—Queensland Health Director-General, Dr David Rosengren,
“This review is not an attempt at resolving different views on these therapies; rather, its findings will help inform future policy relating to the practice. Its findings will help us provide the most appropriate treatment to children and adolescents seeking gender-affirming care,” Dr Roengran said.
Read the full media release on Queensland Health’s website.
Provide your professional input to the review
To provide input or for more information on the review, please visit the Queensland Health Independent review of Stage 1 and Stage 2 hormone therapies in Queensland’s public paediatric gender services webpage.
Public input through written submissions will close Tuesday 29 July 2025. The final report is due to Queensland Health’s Director-General by 30 November 2025.